Cheng Dong

Prof. Cheng Dong

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Bioactive Materials
Verified
Journal Article
Open access
Yun ChangYun Chang
Yun Chang
MCMingyang Chang
Mingyang Chang
XBXiaoping Bao
Xiaoping Bao
CDCheng Dong
Cheng Dong
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against cancers. However, the intricate and resource-intensive autologous cell processing, encompassing collection, expansion, engineering, isolation, and administration, hamper the efficacy of this therapeutic modality. Furthermore, conventional CAR T therapy is presently confined to addressing solid tumors due to impediments posed by physical barriers, the potential for cytokine release syndrome, and cellular exhaustion induced by the immunosuppressive and heterogeneous tumor microenvironment. Consequently, a strategic integration of adoptive immunotherapy with synergistic multimodal treatments, such as chemotherapy, radiotherapy, and vaccine therapy etc., emerges as a pivotal approach to surmount these inherent challenges. This collaborative strategy holds the key to addressing the limitations delineated above, thereby facilitating the realization of more precise personalized therapies characterized by heightened therapeutic efficacy. Such synergistic strategy not only serves to mitigate the constraints associated with adoptive immunotherapy but also fosters enhanced clinical applicability, thereby advancing the frontiers of therapeutic precision and effectiveness.

21 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
PYPeijie Yu
Peijie Yu
BLBin Liu
Bin Liu
CDCheng Dong
Cheng Dong
Yun ChangYun Chang
Yun Chang
A significant increase in life expectancy worldwide has resulted in a growing aging population, accompanied by a rise in aging-related diseases that pose substantial societal, economic, and medical challenges. This trend has prompted extensive efforts within many scientific and medical communities to develop and enhance therapies aimed at delaying aging processes, mitigating aging-related functional decline, and addressing aging-associated diseases to extend health span. Research in aging biology has focused on unraveling various biochemical and genetic pathways contributing to aging-related changes, including genomic instability, telomere shortening, and cellular senescence. The advent of induced pluripotent stem cells (iPSCs), derived through reprogramming human somatic cells, has revolutionized disease modeling and understanding in humans by addressing the limitations of conventional animal models and primary human cells. iPSCs offer significant advantages over other pluripotent stem cells, such as embryonic stem cells, as they can be obtained without the need for embryo destruction and are not restricted by the availability of healthy donors or patients. These attributes position iPSC technology as a promising avenue for modeling and deciphering mechanisms that underlie aging and associated diseases, as well as for studying drug effects. Moreover, iPSCs exhibit remarkable versatility in differentiating into diverse cell types, making them a promising tool for personalized regenerative therapies aimed at replacing aged or damaged cells with healthy, functional equivalents. This review explores the breadth of research in iPSC-based regenerative therapies and their potential applications in addressing a spectrum of aging-related conditions.

14 February 2026 in Biomaterials
Verified
Journal Article
Open access
BDBingyang Dai
Bingyang Dai
LZLizhen Zheng
Lizhen Zheng
James Chung-Wai CheungJames Chung-Wai Cheung
James Chung-Wai Cheung
YLYufeng Long
Yufeng Long
JLJun Liu
Jun Liu
CDCheng Dong
Cheng Dong
Macrophages, as central orchestrators of tissue homeostasis, exhibit remarkable developmental and functional plasticity across diverse physiological and pathological contexts. Mechanistically, microenvironmental cues govern phenotypic switching, while dysregulated crosstalk with stromal cells drives fibrosis and chronic inflammation. Emerging therapeutic strategies targeting macrophages demonstrate potential in restoring tissue homeostasis. However, challenges persist in achieving spatiotemporal precision and balancing pro-repair versus pro-fibrotic outcomes. This review synthesizes current understanding of macrophage biology, encompassing their developmental origins, phenotypic heterogeneity in tissue-specific niches, and multifaceted roles in extracellular matrix (ECM) remodeling, immune surveillance, and organ homeostasis. A comprehensive view of the macrophage regulatory landscape highlights that precise spatiotemporal regulation serves as the cornerstone for macrophages to restore tissue homeostasis. Multiple innovative strategies, including macrophage-based drug delivery systems, cellular and genetic engineering of macrophages, and synergistic macrophage treatment modalities, are expanding the technical frontiers for disease diagnosis and therapeutic intervention. Future directions emphasize integrating multi-omics profiling, synthetic biology, and AI-aided biomaterials to develop 'smart' therapeutics that dynamically steer macrophage functionality. Such synergy will unravel context-dependent signaling and subset-specific interactions, which further advances our understanding of macrophage biology and its translational potential in resolving refractory diseases, and bridges mechanistic insights into transformative clinical applications.

27 October 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
JCJiaqi Cui
Jiaqi Cui
XLXincan LI
Xincan LI
BLBin Liu
Bin Liu
CDCheng Dong
Cheng Dong
Yun ChangYun Chang
Yun Chang
Hematopoietic stem cells (HSCs) are essential for lifelong blood production and immune homeostasis. However, aging induces functional declines in HSCs, leading to hematological disorders, immune dysfunction, and increased susceptibility to malignancies. This review explores the biological underpinnings of HSC aging, highlighting the intrinsic and extrinsic factors that drive this process. We discuss the molecular and cellular mechanisms contributing to HSC aging, including genetic instability, epigenetic alterations, metabolic shifts, and inflammation signaling. Additionally, we examine the role of the bone marrow microenvironment in modulating HSC aging, emphasizing the impact of niche interactions, stromal cell dysfunction, and extracellular matrix remodeling. To advance our understanding of HSC aging, pluripotent stem cell differentiation platforms provide a valuable tool for modeling aged HSC phenotypes and identifying potential therapeutic targets. We review current strategies for HSC rejuvenation, including metabolic reprogramming, epigenetic modifications, pharmacological interventions, and niche-targeted approaches, aiming to restore HSC function and improve regenerative potential. Finally, we present emerging perspectives on the clinical implications of HSC aging, discussing potential translational strategies for combating age-associated hematopoietic decline. By integrating insights from stem cell biology, aging research, and regenerative medicine, this review provides a comprehensive overview of HSC aging and its therapeutic potential. Addressing these challenges will be critical for developing interventions that promote hematopoietic health and improve outcomes in aging populations.

1 October 2025 in Bioactive Materials
Verified
Journal Article
Open access
BLBin Liu
Bin Liu
JSJingqiao Shen
Jingqiao Shen
YWYunhan Wu
Yunhan Wu
CWChun Fai Wong
Chun Fai Wong
THTran Yin Hei
Tran Yin Hei
Yun ChangYun Chang
Yun Chang
Adoptive immune cell-based therapies have shown promise in cancer treatment, yet their efficacy against solid tumors is often limited by the immunosuppressive tumor microenvironment (TME). To overcome these barriers, we design an innovative immune cell cocktail as a combinatorial biomaterial platform, which harnessing the complementary functions of neutrophils and natural killer (NK) cells derived from human pluripotent stem cells (hPSCs). Using CRISPR/Cas9, we introduce an anti-fluorescein isothiocyanate (FITC) chimeric antigen receptor (CAR) construct into the AAVS1 safe harbor locus of hPSCs, allowing for the differentiation of CAR-modified neutrophils and NK cells. These CAR neutrophils exhibit robust anti-tumor activity, forming immune synapses with tumor cells tagged via a bispecific adapter (FITC-folate), even in hypoxic TMEs, while CAR NK cells demonstrate antigen-specific cytotoxicity. Together, the cocktail biomaterial composed of CAR neutrophils and CAR NK cells creates a synergistic anti-tumor effect: having neutrophils enhance TME modulation, and NK cells provide targeted cytotoxicity. This biomaterial offers a scalable and off-the-shelf solution for producing CAR neutrophils and CAR NK cells, potentially reducing needs for high-dose exogenous cytokines and minimizing immune-related toxicities. Our findings suggest that hPSC-derived CAR neutrophils and CAR NK cells may form an effective immuno-cocktail biomaterial, offering a feasible strategy for advancing solid tumor immunotherapy through cellular synergy and TME adaptation.

19 July 2025
Verified
Book Chapter
Closed access
PDF file
TLTong Li
Tong Li
BLBin Liu
Bin Liu
CDCheng Dong
Cheng Dong
Yun ChangYun Chang
Yun Chang